Discover

ICCM
IceCure Medical Ltd
5.28
23 x 5.20
14 x 9.10
bid
ask
+
0.42
8.64%
19 @ 06:11 AM
5.31 +0.03 (0.53%)
Ytd-71.15%
1y-82.75%
4.98
day range
5.56
2.12
52 week range
42.00
Open4.98Prev Close4.86Low4.98High5.56Mkt Cap18.09M
Vol339.35KAvg Vol3.27MEPS-7.20P/EN/AForward P/E-4.48
Beta2.63Short Ratio0.46Inst. Own0.40%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-1250-d Avg6.45200-d Avg16.891yr Est3.37
Earning
DateForEstimateReportedSurprisesurprise %
2024-11-262024-09-0.07-0.08-0.01-14.29%
2024-08-202024-06-0.07N/AN/AN/A
2024-08-202024-06-0.07-0.060.0114.29%
2024-05-282024-03-0.08N/AN/AN/A
2024-05-282024-03-0.08-0.08N/AN/A
2024-04-032023-120-0.07N/AN/A
Upgrade / Downgrade
DateFirmActionFromTo
2024-11-27HC Wainwright & Co.UpgradeBuyBuy
2024-11-08HC Wainwright & Co.UpgradeBuyBuy
2024-09-12HC Wainwright & Co.UpgradeBuyBuy
2024-08-21HC Wainwright & Co.UpgradeBuyBuy
2024-07-02HC Wainwright & Co.UpgradeBuyBuy
2024-06-05HC Wainwright & Co.UpgradeBuyBuy
Profile
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
Institution Ownership
Report DateOrganizationPositionValuePercentage
Fund Ownership
Report DateOrganizationPositionValuePercentage
Split
SplitDate
1 : 302026-06-04
1 : 82021-08-09